Table 3.

Derivation of treatment initiation criteria and components of GELF, BNLI, and GITMO criteria available in MER database.

Any treatment initiation criteria (applied for the analysis)	GELF criteria	GITMO criteria	BNLI criteria
High tumor burden defined by —A tumor >10 cm (1.5%, n = 6, missing = 5), or >2 nodes in 3 distinct areas each >3 cm (2.7%, n = 11, missing = 19)	High tumor burden defined by —A tumor >7 cm,b or >2 nodes in 3 distinct areas each > 3 cma	Extra nodal diseasea	Rapid generalized disease progression in the last 3 months
Symptomatic splenic enlargement (4.5%, n = 18, missing = 3)	Symptomatic splenic enlargementa	Spleen enlargementa	Life-threatening organ involvement
Presence of systemic symptoms (ECOG PS > 1) (2.8%, n = 11, missing = 4)	Organ compression	Leukemia phasea	Renal or macroscopic liver infiltrationa (4.9%, n = 20, missing = 0)
Serum LDH > ULN (10%, n = 40, missing = 44)	Ascites or pleural effusion	Serous effusions	Bone lesionsa (2.0%, n = 8, missing = 0)
Β2-microglobulin > ULN (21%, n = 85, missing = 261)	Presence of systemic symptoms (ECOG PS > 1)a	Nodal or extranodal mass >7 cmb	Presence of systemic symptomsa
Extra nodal disease (27%, n = 110, missing = 0)	Serum LDH > ULNa	>2 nodal masses, each >3 cma	Hemoglobin <10 g/dLa
Leukemia phase (4.7%, n = 19, missing = 0)	Β2-microglobulin > ULNa	B symptomsa	WBC < 3.0 × 109 related to marrow infiltrationa
B symptoms (3.0%, n = 12, missing = 1)		Presence of systemic symptoms (ECOG PS > 1)a
Cytopenia due to marrow infiltration; Hemoglobin < 10 g/dL; WBC < 3.0 × 109 related to marrow infiltration (1.0%, n = 4, missing = 0)		Serum LDH or Β2-microglobulin > ULNa
		ESR > ULN
		Cytopenia due to marrow infiltrationa
Bone lesions (2.0%, n = 8, missing = 0)

PS performance status, LDH lactate dehydrogenase, ULN upper limit of normal, ESR erythrocyte sedimentation rate, WBC white blood cell count.

^aCaptured in MER as described in the criteria

^bCaptured in MER with different cut off value, nodal mass >10 cm instead of 7 cm.